IRF7
Basic information
Region (hg38): 11:612553-615983
Links
Phenotypes
GenCC
Source:
- immunodeficiency 39 (Limited), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Immunodeficiency 39 | AR | Allergy/Immunology/Infectious | An individual has been described as developing severe respiratory distress following influenza infection, and awareness may allow preventive measures and rapid management | Allergy/Immunology/Infectious | 25814066 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the IRF7 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 139 | 153 | ||||
missense | 279 | 286 | ||||
nonsense | 9 | |||||
start loss | 0 | |||||
frameshift | 19 | 19 | ||||
inframe indel | 3 | |||||
splice donor/acceptor (+/-2bp) | 8 | |||||
splice region | 20 | 14 | 4 | 38 | ||
non coding | 69 | 13 | 88 | |||
Total | 0 | 0 | 331 | 213 | 22 |
Variants in IRF7
This is a list of pathogenic ClinVar variants found in the IRF7 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-612604-TGGGCTGCTCCAGCTTTCTGGAGTTCTCATTAGACTGGGTTCTAGGC-T | Immunodeficiency 39 | Uncertain significance (Aug 27, 2022) | ||
11-612649-G-A | Immunodeficiency 39 | Uncertain significance (Oct 26, 2022) | ||
11-612651-G-A | Immunodeficiency 39 | Likely benign (Jul 26, 2023) | ||
11-612667-A-G | Immunodeficiency 39 | Uncertain significance (Jul 17, 2023) | ||
11-612678-C-G | Immunodeficiency 39 | Uncertain significance (May 19, 2023) | ||
11-612680-C-G | Immunodeficiency 39 | Uncertain significance (Apr 10, 2021) | ||
11-612680-C-T | Immunodeficiency 39 | Uncertain significance (Jan 25, 2024) | ||
11-612681-G-A | Immunodeficiency 39 | Likely benign (Nov 04, 2020) | ||
11-612681-G-T | Immunodeficiency 39 | Likely benign (Oct 03, 2023) | ||
11-612686-C-T | Immunodeficiency 39 | Uncertain significance (Oct 03, 2019) | ||
11-612687-G-A | Immunodeficiency 39 | Likely benign (Jan 20, 2024) | ||
11-612689-C-T | Immunodeficiency 39 | Uncertain significance (Sep 26, 2022) | ||
11-612696-G-T | Immunodeficiency 39 | Uncertain significance (May 22, 2023) | ||
11-612704-C-T | Immunodeficiency 39 • not specified | Conflicting classifications of pathogenicity (Dec 26, 2023) | ||
11-612705-G-A | Immunodeficiency 39 • IRF7-related disorder | Likely benign (Feb 06, 2022) | ||
11-612705-G-T | Immunodeficiency 39 | Uncertain significance (Aug 26, 2021) | ||
11-612713-G-A | Immunodeficiency 39 | Likely benign (Apr 23, 2022) | ||
11-612723-G-A | Immunodeficiency 39 | Likely benign (Mar 18, 2022) | ||
11-612734-T-C | Immunodeficiency 39 | Uncertain significance (Sep 17, 2023) | ||
11-612738-C-T | Immunodeficiency 39 | Uncertain significance (Feb 06, 2023) | ||
11-612742-G-C | Immunodeficiency 39 | Uncertain significance (Sep 16, 2022) | ||
11-612747-C-T | Immunodeficiency 39 | Likely benign (Nov 08, 2023) | ||
11-612751-C-T | Immunodeficiency 39 | Uncertain significance (Apr 23, 2023) | ||
11-612757-C-A | Immunodeficiency 39 | Uncertain significance (Dec 27, 2023) | ||
11-612761-G-C | not specified | Uncertain significance (May 30, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
IRF7 | protein_coding | protein_coding | ENST00000397566 | 9 | 3447 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
4.45e-15 | 0.00656 | 125370 | 0 | 40 | 125410 | 0.000159 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.851 | 368 | 325 | 1.13 | 0.0000219 | 3196 |
Missense in Polyphen | 111 | 124.87 | 0.8889 | 1311 | ||
Synonymous | -2.84 | 193 | 149 | 1.30 | 0.0000108 | 1113 |
Loss of Function | -0.374 | 21 | 19.2 | 1.09 | 8.25e-7 | 222 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000518 | 0.000495 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000278 | 0.000247 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Key transcriptional regulator of type I interferon (IFN)-dependent immune responses and plays a critical role in the innate immune response against DNA and RNA viruses. Regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters. Can efficiently activate both the IFN-beta (IFNB) and the IFN-alpha (IFNA) genes and mediate their induction via both the virus-activated, MyD88- independent pathway and the TLR-activated, MyD88-dependent pathway. Required during both the early and late phases of the IFN gene induction but is more critical for the late than for the early phase. Exists in an inactive form in the cytoplasm of uninfected cells and following viral infection, double-stranded RNA (dsRNA), or toll-like receptor (TLR) signaling, becomes phosphorylated by IKBKE and TBK1 kinases. This induces a conformational change, leading to its dimerization and nuclear localization where along with other coactivators it can activate transcription of the type I IFN and ISG genes. Can also play a role in regulating adaptive immune responses by inducing PSMB9/LMP2 expression, either directly or through induction of IRF1. Binds to the Q promoter (Qp) of EBV nuclear antigen 1 a (EBNA1) and may play a role in the regulation of EBV latency. Can activate distinct gene expression programs in macrophages and regulate the anti-tumor properties of primary macrophages. {ECO:0000269|PubMed:11073981, ECO:0000269|PubMed:12374802, ECO:0000269|PubMed:15361868, ECO:0000269|PubMed:17404045}.;
- Disease
- DISEASE: Immunodeficiency 39 (IMD39) [MIM:616345]: A primary immunodeficiency causing severe, life-threatening acute respiratory distress upon infection with H1N1 influenza A. {ECO:0000269|PubMed:25814066}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human);Influenza A - Homo sapiens (human);Cytosolic DNA-sensing pathway - Homo sapiens (human);Toll-like receptor signaling pathway - Homo sapiens (human);NOD-like receptor signaling pathway - Homo sapiens (human);Viral carcinogenesis - Homo sapiens (human);Hepatitis C - Homo sapiens (human);Hepatitis B - Homo sapiens (human);Measles - Homo sapiens (human);RIG-I-like receptor signaling pathway - Homo sapiens (human);Herpes simplex infection - Homo sapiens (human);Regulation of toll-like receptor signaling pathway;Apoptosis;Structural Pathway of Interleukin 1 (IL-1);Apoptotic Signaling Pathway;TLR4 Signaling and Tolerance;Toll-like Receptor Signaling;RIG-I-like Receptor Signaling;Ebola Virus Pathway on Host;Ebola Virus Pathway on Host;Senescence and Autophagy in Cancer;Toll-like Receptor Signaling Pathway;Toll Like Receptor 7/8 (TLR7/8) Cascade;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;the information processing pathway at the ifn beta enhancer;Cytokine Signaling in Immune system;Toll Like Receptor 9 (TLR9) Cascade;TICAM1-dependent activation of IRF3/IRF7;Toll Like Receptor 3 (TLR3) Cascade;Toll-Like Receptors Cascades;TRAF6 mediated IRF7 activation;DDX58/IFIH1-mediated induction of interferon-alpha/beta;DEx/H-box helicases activate type I IFN and inflammatory cytokines production ;Innate Immune System;Immune System;TRAF3-dependent IRF activation pathway;MyD88 dependent cascade initiated on endosome;Interferon gamma signaling;Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon;Cytosolic sensors of pathogen-associated DNA ;TRIF(TICAM1)-mediated TLR4 signaling ;MyD88-independent TLR4 cascade ;Toll Like Receptor 4 (TLR4) Cascade;Interferon alpha/beta signaling;Interferon Signaling;Regulation of nuclear SMAD2/3 signaling
(Consensus)
Recessive Scores
- pRec
- 0.369
Intolerance Scores
- loftool
- 0.0953
- rvis_EVS
- -0.27
- rvis_percentile_EVS
- 34.82
Haploinsufficiency Scores
- pHI
- 0.135
- hipred
- Y
- hipred_score
- 0.566
- ghis
- 0.539
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.888
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Irf7
- Phenotype
- immune system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;regulation of adaptive immune response;transcription by RNA polymerase II;cellular response to DNA damage stimulus;response to virus;immunoglobulin mediated immune response;establishment of viral latency;regulation of type I interferon production;positive regulation of type I interferon production;interferon-alpha production;interferon-beta production;positive regulation of interferon-alpha production;positive regulation of interferon-beta production;regulation of MyD88-dependent toll-like receptor signaling pathway;regulation of MyD88-independent toll-like receptor signaling pathway;TRIF-dependent toll-like receptor signaling pathway;MDA-5 signaling pathway;innate immune response;type I interferon biosynthetic process;regulation of monocyte differentiation;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;regulation of immune response;defense response to virus;interferon-gamma-mediated signaling pathway;type I interferon signaling pathway;positive regulation of type I interferon-mediated signaling pathway;negative regulation of macrophage apoptotic process
- Cellular component
- nucleus;nucleoplasm;cytoplasm;cytosol;endosome membrane
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA binding;protein binding